Search Results for "CT P6 Celltrion"

12:56 EDT 18th October 2017 | BioPortfolio

Matching Channels


Matching News

Celltrion Healthcare $890m IPO to up biosimilar inventory and broaden portfolio

Celltrion Healthcare will purchase more biosimilars from biomanufacturing partner Celltrion Inc. and expand its distribution network after raising one trillion Won ($888m) in an IPO.

Celltrion Healthcare IPO To Accelerate Celltrion's Global Biosimilar Expansion

Celltrion Healthcare's initial public offering, which is seen as the most anticipated biotech IPO in South Korea's Kosdaq market this...   

Data show equivalence of Celltrion's copycat to reference drug rituximab

South Korean biopharmaceutical firm Celltrion has showcased data supporting the efficacy and safety of…

Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed ...

Teva Pharmaceutical Industries Ltd.IR Contacts:United StatesKevin C. Mannix, 215-591-8912Ran Meir, 215-591-3033orIsraelTomer Amitai, 972 (3) 926-7656orPR Contacts:IsraelIris Beck ...

Celltrion And Teva Say FDA Accepts BLA For Proposed Biosimilar To Herceptin

PETAH TIKVA (dpa-AFX) - Celltrion Inc. and Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for ...

Teva And Celltrion Say FDA Accepts BLA For Proposed Biosimilar To Rituxan

PETAH TIKVA (dpa-AFX) - Celltrion Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration has accepted for rev...

Celltrion making progress with biosimilars in China and Japan

South Korean biotechnology company Celltrion has announced advances in its biosimilar rituximab and trastuzumab programmes in China and Japan.

FDA accepts Teva, Celltrion's BLA for Rituxan biosimilar

The FDA has accepted Celltrion and Teva Pharmaceutical Industries' biologics license application for CT-P10, a biosimilar to  -More- 

Matching PubMed Articles


Search Whole site using Google

Quick Search
Advertisement Advertisement